Table 1.
Characteristics of the study population at cHL diagnosis.
| Patients with Pre-Diagnosis Samples (n = 7) | Patients with a 24-Month Immunological Follow-Up (n = 38) | ||
|---|---|---|---|
| Age (years) | |||
| Median | 42 | 43 | |
| IQR | 39–53 | 38–47 | |
| Gender | |||
| M | 7 | 33 | |
| F | 0 | 5 | |
| Lymphoma stage | |||
| I-II | 0 | 8 | |
| III-IV | 7 | 30 | |
| Histology | |||
| Nodular Sclerosis | 1 (14.3) | 3 (7.9) | |
| Mixed Cellularity | 4 (57.1) | 27 (71.1) | |
| Lymphocyte Predominance | 0 (0.0) | 1 (2.6) | |
| Not categorized | 2 (28.6) | 7 (18.4) | |
| Immunological Markers | |||
| IL10 (pg/mL) | |||
| Median | 20.3 | 32.2 | |
| IQR | 17.5–157.1 | 14.5–75.4 | |
| IL6 (pg/mL) | |||
| Median | 60.5 | 27.7 | |
| IQR | 6.8–266.4 | 8.1–60.5 | |
| BAFF (pg/mL) | |||
| Median | 2075.1 | 2024.2 | |
| IQR | 585.1–4381.0 | 913.7–4288.9 | |
| CD4+ T-cells (Cells/μL of blood) | |||
| Median | 465 | 380 | |
| IQR | 127–596 | 144–483 | |
| CD8+ T-cells (Cells/μL of blood) | |||
| Median | 692 | 544 | |
| IQR | 410–1806 | 394–784 | |
| CD19+ B-cells (Cells/μL of blood) | |||
| Median | 161 | 56 | |
| IQR | 26–196 | 16–153 | |
| CD3+CD4+ T-cells (Cells/μL of blood) | |||
| Median | 487 | 267 | |
| IQR | 234–579 | 125–510 | |
| CD3+CD8+ T-cells (Cells/μL of blood) | |||
| Median | 788 | 496 | |
| IQR | 427–1357 | 325–788 | |
| CD56+CD16+ NK-cells (Cells/μL of blood) | |||
| Median | 160 | 127 | |
| IQR | 105–256 | 76–177 |
cHL: classical Hodgkin lymphoma; IQR: interquartile range; NK: natural killer.